30 Oct 2025 | 5 Mins Read
Dr. Reddy's Laboratories under pressure due to negative development
Flipitmoney
Dr. Reddy's Laboratories received a Notice of Non-Compliance for its Semaglutide injection from the Canadian drug regulator. The company will resubmit with additional information and remains confident in the product's quality, safety, and comparability, with analysts expecting Canadian approval by March 2026 and potential revenue of $100 million for FY2027.